Eli Lilly and CoChange company Symbol lookupSelect an option...LLY Eli Lilly and CoAVNI Arvana IncARCC Ares Capital CorpBCDA BioCardia IncAFG American Financial Group IncMGEN miRagen Therapeutics IncCVLG Covenant Logistics Group IncARLO Arlo Technologies IncBAC Bank of America CorpPWOD Penns Woods Bancorp IncGo
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Valuation Ratios
- Price/Earnings (TTM)
- 24.14x
- Price/Sales (TTM)
- 6.08x
- Price/Book (MRQ)
- 29.22x
- Price/Cash Flow (TTM)
- 20.53x
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in millions.
Cash flow
Values displayed are in millions.
Company Officers
- David A. RicksChmn.
- Joshua L. SmileyCFO
- Aarti ShahSr.VP
- Daniel M. SkovronskySr.VP
- Melissa Stapleton BarnesSr.VP
Address
- Lilly Corporate Ctr
- Indianapolis, IN 46285-0001
- Phone: (317) 276-2000
- Fax: (317) 276-3492
- https://www.lilly.com/
Insider Trading
During the most recent quarter, 1M shares were sold in insider trading.
Insider trading information report provided by Copyright © 2020. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.